Horizon Pharma PLC (HZNP) Stake Decreased by Fiera Capital Corp

Fiera Capital Corp lessened its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 44.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 738,858 shares of the biopharmaceutical company’s stock after selling 583,354 shares during the quarter. Fiera Capital Corp owned about 0.45% of Horizon Pharma PLC worth $8,771,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of HZNP. Profund Advisors LLC raised its position in Horizon Pharma PLC by 0.8% in the 1st quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 112 shares during the last quarter. Wells Fargo & Company MN raised its position in Horizon Pharma PLC by 12.6% in the 1st quarter. Wells Fargo & Company MN now owns 498,787 shares of the biopharmaceutical company’s stock valued at $7,372,000 after purchasing an additional 55,678 shares during the last quarter. American Century Companies Inc. raised its position in Horizon Pharma PLC by 12.4% in the 1st quarter. American Century Companies Inc. now owns 547,464 shares of the biopharmaceutical company’s stock valued at $8,092,000 after purchasing an additional 60,356 shares during the last quarter. US Bancorp DE raised its position in Horizon Pharma PLC by 1.2% in the 1st quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock valued at $473,000 after purchasing an additional 368 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Horizon Pharma PLC by 3.1% in the 1st quarter. Bank of New York Mellon Corp now owns 764,571 shares of the biopharmaceutical company’s stock valued at $11,300,000 after purchasing an additional 22,918 shares during the last quarter. Institutional investors and hedge funds own 82.30% of the company’s stock.

WARNING: “Horizon Pharma PLC (HZNP) Stake Decreased by Fiera Capital Corp” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/17/horizon-pharma-plc-hznp-stake-decreased-by-fiera-capital-corp.html.

Several analysts recently commented on the stock. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Sunday, September 10th. BidaskClub downgraded shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. ValuEngine downgraded shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BMO Capital Markets reiterated an “outperform” rating and issued a $18.00 price target (up previously from $17.00) on shares of Horizon Pharma PLC in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a research report on Monday, September 11th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $18.67.

Horizon Pharma PLC (NASDAQ HZNP) opened at 12.11 on Friday. The stock’s market cap is $1.98 billion. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The firm’s 50-day moving average is $12.81 and its 200-day moving average is $13.04.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. The firm had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The firm’s revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.56 earnings per share. On average, equities analysts forecast that Horizon Pharma PLC will post $1.08 earnings per share for the current fiscal year.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply